Featured Research

from universities, journals, and other organizations

Genetic variations linked with worse outcomes with use of antiplatelet drug for cardiac procedures

Date:
October 27, 2010
Source:
JAMA and Archives Journals
Summary:
An analysis of data from previously published studies indicates that use of the antiplatelet drug clopidogrel for patients who have common genetic variants of a certain gene and are undergoing a procedure such as coronary stent placement have an associated increased risk for major adverse cardiovascular events, particularly development of blood clots in stents, according to a new study.

An analysis of data from previously published studies indicates that use of the antiplatelet drug clopidogrel for patients who have common genetic variants of a certain gene and are undergoing a procedure such as coronary stent placement have an associated increased risk for major adverse cardiovascular events, particularly development of blood clots in stents, according to a study in the October 27 issue of JAMA.

Clopidogrel, one of the most commonly prescribed medications, has been shown to reduce cardiovascular events in patients undergoing percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries). "However, there is a large degree of interindividual variability in the pharmaco-dynamic response to clopidogrel," the authors write. Data suggest its pharmacologic effect varies based on variations of the gene CYP2C19, but there is uncertainty regarding the clinical risk given by certain variations.

Jessica L. Mega, M.D., M.P.H., of Brigham and Women's Hospital and Harvard Medical School, Boston, and colleagues conducted a meta-analysis to determine the risk of major adverse cardiovascular outcomes among carriers of 1 or 2 reduced-function CYP2C19 genetic variants in patients treated with clopidogrel. The analysis included data from 9 studies and 9,685 patients (of whom 91.3 percent underwent PCI and 54.5 percent had an acute coronary syndrome), 863 experienced the composite outcome of cardiovascular death, heart attack, or stroke; and 84 patients had stent thrombosis (blood clot) among the 5,894 evaluated for such.

There were 6,923 patients (71.5 percent) with no CYP2C19 reduced-function alleles (an alternative form of a gene), 2,544 (26.3 percent) with 1 reduced-function CYP2C19 allele, and 218 (2.2 percent) with 2 reduced-function CYP2C19 alleles. "Compared with CYP2C19 noncarriers, there was a significantly increased risk of cardiovascular death, myocardial infarction, or stroke in the 26.3 percent of the overall study population who carried only 1 reduced-function CYP2C19 allele. Similarly, there was a significantly increased risk of cardiovascular death, myocardial infarction, or stroke in the 2.2 percent of the overall study population who carried 2 reduced-function CYP2C19 alleles," the researchers write.

The authors also found that both carriers of only 1 reduced-function CYP2C19 allele and carriers of 2 alleles were at significantly increased risk of stent thrombosis when compared with CYP2C19 noncarriers.

"In conclusion, the findings of this collaborative meta-analysis demonstrate that common genetic variants in the CYP2C19 gene are associated with almost 1 in 3 patients not receiving ideal protection from ischemic events when treated with standard doses of clopidogrel for PCI. Given how widely clopidogrel is used to treat patients with cardiovascular disease, determination of the optimal antiplatelet treatment doses or regimens for individual patients is needed to tailor therapy appropriately," the authors write.

Editorial: Clopidogrel and the Reduced-Function CYP2C19 Genetic Variant

In an accompanying editorial, Valentin Fuster, M.D., Ph.D., of the Mount Sinai School of Medicine, New York, and Joseph M. Sweeny, M.D., of the Mount Sinai Medical Center, comment on the findings of this meta-analysis.

" … in patients treated with clopidogrel, the best genome-guided strategy remains to be determined. The information obtained by CYP2C19 genetic testing may be particularly useful in patients at risk of poor outcomes, either because they have already had an adverse event (e.g., stent thrombosis) or other at-risk characteristics such as diabetes mellitus, chronic renal failure, or angiographic high-risk features."

They add that until other ongoing studies that are investigating the best genome-guided strategy for higher-risk patients are completed, "clopidogrel and CYP2C19 genetic testing appear to be only a limited piece of the overall therapeutic puzzle of clopidogrel therapy and personalized medicine."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal References:

  1. J. L. Mega, T. Simon, J.-P. Collet, J. L. Anderson, E. M. Antman, K. Bliden, C. P. Cannon, N. Danchin, B. Giusti, P. Gurbel, B. D. Horne, J.-S. Hulot, A. Kastrati, G. Montalescot, F.-J. Neumann, L. Shen, D. Sibbing, P. G. Steg, D. Trenk, S. D. Wiviott, M. S. Sabatine. Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI: A Meta-analysis. JAMA: The Journal of the American Medical Association, 2010; 304 (16): 1821 DOI: 10.1001/jama.2010.1543
  2. V. Fuster, J. M. Sweeny. Clopidogrel and the Reduced-Function CYP2C19 Genetic Variant: A Limited Piece of the Overall Therapeutic Puzzle. JAMA: The Journal of the American Medical Association, 2010; 304 (16): 1839 DOI: 10.1001/jama.2010.1566

Cite This Page:

JAMA and Archives Journals. "Genetic variations linked with worse outcomes with use of antiplatelet drug for cardiac procedures." ScienceDaily. ScienceDaily, 27 October 2010. <www.sciencedaily.com/releases/2010/10/101026161249.htm>.
JAMA and Archives Journals. (2010, October 27). Genetic variations linked with worse outcomes with use of antiplatelet drug for cardiac procedures. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2010/10/101026161249.htm
JAMA and Archives Journals. "Genetic variations linked with worse outcomes with use of antiplatelet drug for cardiac procedures." ScienceDaily. www.sciencedaily.com/releases/2010/10/101026161249.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins